Background: In vitro, thymidylate synthase (TS) inhibition by 5-fluorouracil (5-FU) induces thymineless apoptosis possibly via Fas receptor-Fas ligand interactions and cell-cycle arrest. In colorectal cancer patients we evaluated whether 5-FU administration also resulted in apoptosis and cell-cycle arrest and which proteins might be involved.
Introduction
For decades 5-fluorouracil (5-FU) has been the standard first-line chemotherapeutic agent with low but consistent activity against colorectal adenocarcinoma. In combination with leucovorin (LV) the response rate increased from 10%-20% to 20%-30% [1, 2] . The target enzyme for 5-FU, thymidylate synthase (TS), catalyses the conversion of deoxyuridine-5'-monophosphate (dUMP) to deoxythymidine-5'-monophosphate (dTMP), and is essential for DNA synthesis. 5,10-Methylene-tetrahydrofolate (CH 2 -THF) is the limiting methyl donor during this reaction [3, 4] . The active metabolite of 5-FU, 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) can form a ternary complex with TS and CH 2 -THF leading to TS inhibition [5, 6] , growth arrest and cell death [7] . This complex formation is stimulated by LV [8, 9] . Although TS inhibition is an important mechanism of 5-FU cytotoxicity, 5-FU is also incorporated into RNA [10] and DNA [11] .
Resistance to 5-FU treatment might not only depend on factors involved in classical resistance mechanisms [12] , such as the expression or activity of TS, but also on mechanisms involved in cell growth inhibition or programmed cell death [7, 13, 14] . Cell-cycle progression is controlled by p53 [15, 16] , p21 [17] , Rb and E2F [18] . Upon drug treatment induced DNA damage, p53 activates p21 to initiate cell-cycle arrest. The tumor suppressor gene Rb forms a complex with E2F1 and E2F2 inhibiting their transcriptional activity [19] . After phosphorylation of Rb by specific kinases, cell-cycle progression can be activated by release of E2F1 and E2F2.
Besides its role in cell-cycle regulation, p53 is also involved in the activation of apoptosis [16] by induction of the expression of bax [20] . An excess of bax transactivates apoptosis whereas BCL-2, BCL-xl and mcl-1 protect cells against apoptosis [21, 22] . The expression of the Fas receptor can also be increased by/;5J [23] . Fas is expressed on a wide variety of tissue types including normal and neoplastic colonic epithelium [24] and can be activated by Fas ligand. This will activate caspase-8 followed by activation of caspase-3 [25] , and will result in the induction of apoptosis [26] . Caspase-3 which is thought to be the final executioner of apoptosis, mediates processes such as oligonucleosomal DNA fragmentation, cell membrane blebbing and formation of apoptotic bodies [27, 28] by cleavage of structural proteins (e.g.. actin, lamin and intermediate filaments such as cytokeratin 18 in epithelial cells [29] ) and functional proteins (e.g., the DNA repair enzyme poly-(ADP-ribose)-polymerase(PARP [30] ).
The effect of 5-FU on the expression of cell cycle and apoptosis regulatory proteins has been investigated in various model systems [7, 31] , but information from tumour samples of cancer patients after treatment is scarce since tumor samples are not easily available after drug administration. In a limited amount of samples from patients with advanced colorectal cancer we could evaluate whether 5-FU administration induced apoptosis and cell-cycle arrest. To best delineate which proteins might be involved in these processes, the expression of 15 different markers was investigated. Three different time points (2, 22 and 46 hours) were chosen to determine the time dependency of these markers.
Patients and methods

Patients
Patients with histologically proven metastases of colorectal cancer were entered into this study. Resection specimens of liver metastases were obtained from 28 male and 20 female patients with a median age of 55 years (ranging form 34 to 77 years). A total of 36 patients received an intravenous bolus injection of 5-FU at different time points before surgery (Table 1) . Twelve patients who did not receive 5-FU served as a control group (group 1). Intervals between 5-FU injection and resection were planned to be 2, 24 and 48 hours, but due to variations in scheduling of surgery, the actual interval varied for group 2 from I to 2 hours (7 patients, median of 2 hours), for group 3 from 19 to 25 hours (6 patients, median of 22 hours), and for group 4 from 39 to 50 hours (23 patients, median of 46 hours). Seventeen patients in group 4 also received LV before surgery. Eight patients received I-LV (250 mg/m 2 ) and two patients dl-LV (500 mg/m 2 ) as a two-hour intravenous infusion, with 5-FU administration in the middle of the infusion. To seven patients. dl-LV (25 mg/m 2 ) was administered as a bolus injection one hour before 5-FU. Informed consent was obtained from all patients before drug administration and surgery.
Chemicals
Primary antibodies were obtained from several sources as summarised in Table 2 . Biotinylated goat-anti-mouse immunoglobuhnes. normal goat serum and streptavidin-biotin conjugated horse radish peroxidase (sABC-HRP) were obtained from DAKO (Glostrup, Denmark) and biotinylated goat-anti-rabbit immunoglobulines from Vector Laboratories (Burlinghame. California. USA). Saponine, streptavidine, D-biotin. poly-L-lysine and di-amino-benzidine-HCL (DAB) were purchased from Sigma-Aldrich Chemie BV (Zwijndrecht.The Netherlands) Unless otherwise specified, all other chemicals were of analytical grade and commercially available
Immunohistochemical staining
Resection specimens were obtained from colorectal cancer patients with liver metastases, immediately frozen in liquid nitrogen and subsequently stored at -80 °C. Frozen tissue sections (4 urn) were mounted on poly-L-lysine (0.1%) coated slides and subsequently fixed for 10 min with either acetone (100%) or freshly prepared paraformaldehyde (4% in phosphate buffered saline (PBS)) depending on the primary anti- The median age of patients who received 5-FU two hours before biopsies were taken, was significantly lower (P -0.04) compared with the other three group No differences between the four groups were observed for the other characteristics.
body (Table 2 ). Thereafter, endogenous peroxidase was quenched by incubation with PBS/H 2 O 2 (l%)/NaN., (0.02%) Endogenous biotin was blocked in all sections (acetone and paraformaldehyde (paraform)) using streptavidine (0.01%) and subsequently incubated with D-biotin (0.01%) supplemented with normal goal serum (I : 50). After 20 min, slides were incubated with the primary antibodies which were detected with biotinylated secondary antibodies for 30 min. Staining was developed by incubation of sections with sABC-HRP (1:200; 1 hour) and visualised by DAB (0.5 mg/ml) with 0.025% H 2 O 2 for 3 min. For Fas ligand, caspase-3 and PARP an additional amplification step with CARD enhancement kit (DAKO) was needed followed by a second incubation with sABC-HRP (1:200; 30 min) before DAB visualisation (CARD method [32] ). PBS/glucose (0.1%) was used for washing procedures of acetone tissue sections, whereas for paraform fixed sections also 0.1% saponine was added to the washing buffer. All slides were counterstained with hematoxylin. Negative controls were performed for each sample by omitting the primary antibody.
Immunohistochemical scoring
A pathologist (EB) and two investigators (DF and HB) evaluated slides for each antibody without knowledge of the clinical history and outcome As published before, p53 [33. 34] , p2l. Ki67, Rb [33] and BCL-2 [34, 60] were evaluated by scoring the percentage of positive tumour cells in 4 categories (<25%, 26%-50%. 51%-75% and 76%-100%). ForTS [35. 36, 55] . Rb, Fas ligand [37. 38] , PARP, E2F2 and caspase-3 the intensity of the staining was taken into account because these proteins were expressed in almost all tumour cells. The intensity was divided in three categories: low, intermediate or high. Bax [39] , mcl-1 and BCL-xl [39] were evaluated by scoring the punctation pattern of their expression, diffuse and peri-nuclear punctation. Fas receptor was only evaluated as negative or positive. In all cases the inter-observer variability was < 10%
Positive controls included normal colon mucosa (for Fas receptor. Fas ligand, p2l, Rb, PARP, Ki67 and E2F2), tonsils (for Fas ligand, BCL-2. bax and caspase-3), tumour cells with high protein expression (for all tested antibodies) and the internal controls in the samples such as normal liver (for Fas receptor, Rb and caspase-3 [40] ) and lymphocytes (for BCL-2).
Quantification of the M30 immunostaining
The percentage of M30 positive tumour cells was quantified using a commercially available interactive video-overlay-based measuring system (Q-PRODIT, Leica. Cambridge. UK). The microscopic image was recorded by a CCD camera and displayed on a monitor. Two hundred fields of vision were systematically randomly selected using an automatic scanning stage controlled by a computer [41, 42] . In these fields, a total of at least 200 neoplastic cells, as determined by morphology. [55] p53 [36, 56] P 21 [57] Ki67 [56] Rb [58] E2F2 Fas receptor [59] Fasligand a [38] BCL-2 [56, 57, 60] 
BCL-x[6\]
Bax [62] Mcl-l [63] Caspase-3" [64] PARP" [65] M30 cytodeath [66] 
Statistical methods
Statistical evaluation was performed using the non-parametric KruskalWallis and Mann-Whitney U ranking test. All values were based on two-tailed statistical analysis. The first test was used to evaluate significant differences between all four groups, whereas in the second test, differences were evaluated between two groups. Differences between the four groups were considered significant when P < 0.05. Differences with a />-value between 0.05-0.08 were also taken into account when they are in line with data previously published. All statistical procedures were carried out with SPSS 9.0 (SPSS Inc., Chicago, Illinois, USA).
Results
The expression of 15 cell-cycle and apoptosis dependent markers (Table 3 (Table 3) .
Cell-cycle related expression
The intensity of the expression of the target enzyme TS was lower {P -0.058) in liver metastases from the patient group who received 5-FU two hours before resection compared with the control group (Figure 1 ). Seventy percent of the metastases had a high TS expression (> intermediate (+)) in the control group, whereas only fourteen percent showed a high (++) expression in the two hours group. After 46 hours, the expression of TS (50% of the metastases showed a high TS expression) was as high as in the control group (P = 0.07) (Figure 1 ). The percentage of tumour cells positive for the proliferation marker Ki67 was significantly lower 2 (P = 0.001) and 46 hours {P = 0.047) after 5-FU administration compared to the control group (Figures 2a, 3a and 3b) . Eighty-two percent of the metastases of the control group showed high expression of Ki67 (with > 50% positive tumour cells), whereas this percentage was lower 
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The percentage and intensity of immunoreactive tumor cells for the cell-cycle and apoptosis proteins were dichotomised into two groups. For each group the number of patients is given. The cut-off points for p53. p2I and BCL-2 expression were according to Sinicrope et al. [57. 60] . For Fas ligand. caspase-3 and PARP cut-off points were based on intensity. In some metastases samples protein expression was not evaluable due to bad sample quality. Differences between two patient groups indicated with * are found for caspase-3 (control vs. in the two and fourty-six hour groups (43% and 57%, respectively). The expression intensity of E2F2 was also lower (P = 0.01) after two hours of 5-FU administration (Figure 2b ). In the control group, 90% of the metastases expressed high levels of E2F2 (intermediate or high), while in the two hours 5-FU group only 29% had positive tumour cells. After 46 hours, the E2F2 expression was still lower, although not significant (P = 0.077), compared to the control group (Figure 2b ).
Apoptosis related expression
Fas receptor expression was higher in metastases of patients that received 5-FU compared to the control group (P = 0.04; Figures 3c, 3d and 4a ). Almost 50% of the cases had Fas receptor expression 46 hours after 5-FU administration compared to almost none in the control group. The expression of caspase-3 also increased (P -0.015) from 57% of the metastases with high caspase-3 expression in the control group to 100% after 22 hours 5-FU. After 46 hours this percentage was lower again (P = 0.036). Furthermore, the levels of PARP which can be cleaved by caspase-3 during apoptosis, increased comparing the 22 hours and the 46 hours bolus group (P = 0.057) ( Table 3 ). The higher expression of Fas receptor, caspase-3 and PARP was associated with an increase of M30 positive Figures 3e and 30 can be utilised specifically to recognise apoptotic cells [66] . The amount of apoptotic cells increased significantly (P < 0.02) from 9% to 13% in the first 3 groups to 22% after 46 hours of 5-FU administration (Figure 4b ).
5-FU and LV
Patients in group 4 were not only injected with singleagent 5-FU but also with the combination 5-FU and different doses of LV. Six patients in the forty-six hour 5-FU group received the single agent and seventeen the combination. Although TS expression was equal among both groups, addition of LV did alter the expression of Rb and p53. The intensity of the Rb expression was higher in patients that received 5-FU + LV (P -0.05). The expression of p53 was elevated (P -0.05) in metastases of patients injected with 5-FU and 250 mg/m 2 LV compared to metastases of patients with 5-FU and 25 mg/m 2 LV (data not shown). 
Discussion
In this report, we demonstrate that after administration of 5-FU tumour cells of metastases ofcolorectal cancer patients show differences in the expression of not only the target enzyme TS but also of cell-cycle and apoptosis related proteins. The TS expression was lower 2 hours after 5-FU administration and higher again after 46 hours, whereas the expression of E2F2 and Ki67 was higher in the control group compared to the patient groups given 5-FU. The expression of Fas receptor and caspase-3, both involved in the activation of apoptosis [25] was elevated after 5-FU which was associated with an increase in apoptosis. In a previous study [8] performed in our department, we demonstrated that TS levels determined by FdUMP binding and catalytic TS activity assays were higher in primary tumours and liver metastases one day after 5-FU injection compared to two hours and two days. TS inhibition was most pronounced two hours after 5-FU. Changes in TS protein expression in the current report are comparable with the TS inhibition data mentioned above although changes did not reach statistical significance (P = 0.06-0.08). Similar results were also obtained in vitro and in vivo after exposure with clinically relevant concentrations of 5-FU [7, 43, 44] . The increase of TS can be explained by the mechanism described by Chu et al. [45] . This process involves the feedback regulation of TS mRNA translation by free TS protein. When TS is inhibited by FdUMP, this feedback regulation is altered resulting in an increase of TS expression. On the other hand, the decrease of TS expression after two hours, which was associated with a decrease in E2F2, could be caused by the down-regulation of TS by E2F1, as described previously [46, 47] and possibly E2F2.
Addition of LV to 5-FU did not have an effect on the expression of TS, although we have shown previously that LV increased the inhibition of TS after 45 hours compared to 5-FU alone [8] and prevented 5-FU induced TS increase in mice [44] . However, immunohistochemistry will detect all TS protein and can not discriminate between freeTS and the ternary complex. Although the number of patients in this group is very low, the expression of Rb and p53 on the other hand, seemed to be higher in patients that received 5-FU + LV. Addition of LV increases TS inhibition which might lead to more effective induction of cell-cycle regulators such as Rb and p53. Elevated levels of Rb might be responsible for cell-cycle arrest by binding to the transcription factor E2F1 [18] , although it must be mentioned that the antibody used in this study recognises both phosphorylated and hypophoshorylated Rb. Increased levels of/;5i might lead to cell-cycle arrest and apoptosis [16] .
A decrease in proliferating cells after 5-FU bolus was clearly demonstrated in the liver metastases by staining with the proliferation marker Ki67. Together with the decrease in E2F2 expression, these results might indicate that 5-FU has an immediate effect on tumour cell proliferation. In primary tumours from 10 patients with advanced colorectal cancer, receiving continuous intravenous 5-FU infusion at a dose of 500 mg/day for 7 days, it was previously shown that the expression of Ki67 decreased compared to tumours of patients not given 5-FU [48] . In addition, cell-cycle arrest as a general effect after TS inhibition was also demonstrated in vitro [49, 50] .
Besides influencing proliferation, administration of 5-FU also had an inducing effect on the Fas receptor, caspase-3 and PARP expression, eventually leading to apoptosis. Expression of the Fas receptor was significantly increased in liver metastases from patients receiving 5-FU compared to the control group. Induction of Fas receptor has also been reported after exposure to anticancer drugs in vitro [23, 51] . Furthermore, cytotoxicity induced by thymineless stress was regulated by autocrine signalling via Fas receptor-Fas ligand interactions [52] . As shown previously, the expression of Fas receptor is high in normal colon mucosa and mostly negative in liver metastases (24) . This might lead to a selection advantage for tumour cells and constitute a mechanism of immune evasion to Fas-mediated killing by infiltrating T cells expressing Fas ligand [53, 54] . TS inhibition by 5-FU seems to restore the normal expression of Fas receptor on tumour cells making them possibly more prone to the induction of apoptosis by T lymphocytes. Yoong et al. [37] already showed that > 85% of lymphocytes infiltrating liver metastases of colorectal cancer express high levels of Fas ligand. Clinical studies combining immunotherapy for activation of cytotoxic T cells and chemotherapy might therefore be very effective.
Increased Fas receptor expression after 5-FU injection was associated with elevated expression of caspase-3 and PARP and with an increase of apoptosis as measured by M30. However, the association between the induction of apoptosis and increased levels of caspase-3 and PARP was not that striking. PARP increase was not significant (P = 0.057) and caspase-3 was elevated only in the patient group receiving 5-FU 22 hours before resection. A explanation for this is that the antibodies used to detect caspase-3 and PARP do not only recognise activated caspase-3 and cleaved PARP, which play a role in the process of apoptosis, but also un-activated caspase-3 and un-cleaved PARP. No differences in apoptosis could be observed when only apoptotic bodies were counted in hematoxylin-eosin stained tissue sections (results not shown). This is probably due to the fact that M30 recognises cells early in the apoptotic pathway whereas the development of picnotic nuclei is a rather late apoptotic event.
In summary, in these unique patient samples, it could be demonstrated that 5-FU induced cell-cycle arrest and increased Fas receptor expression, which was associated with apoptosis. 5-FU induced Fas receptor upregulation might activate Fas signalling leading to activation of caspase-8 and subsequently, caspase-3. Caspase-3 cleaves PARP and cytokeratin 18 leading to apoptosis. Although the number of patients is limited, these results give more insight in the mechanism of 5-FU cytotoxicity and eventually could lead to a better understanding of resistance mechanisms. Furthermore, these results indicate that clinical combination studies of 5-FU with immunotherapy could be very effective.
